Amphastar Pharmaceuticals Total Assets 2012-2026 | AMPH
Amphastar Pharmaceuticals total assets from 2012 to 2026. Total assets can be defined as the sum of all assets on a company's balance sheet.
|
Amphastar Pharmaceuticals Annual Total Assets (Millions of US $) |
|
|---|---|
| 2025 | $1,629 |
| 2024 | $1,577 |
| 2023 | $1,513 |
| 2022 | $742 |
| 2021 | $672 |
| 2020 | $631 |
| 2019 | $587 |
| 2018 | $514 |
| 2017 | $451 |
| 2016 | $428 |
| 2015 | $390 |
| 2014 | $389 |
| 2013 | $339 |
| 2012 | $317 |
| 2011 | $0 |
|
Amphastar Pharmaceuticals Quarterly Total Assets (Millions of US $) |
|
|---|---|
| 2026-03-31 | $1,648 |
| 2025-12-31 | $1,629 |
| 2025-09-30 | $1,666 |
| 2025-06-30 | $1,615 |
| 2025-03-31 | $1,626 |
| 2024-12-31 | $1,577 |
| 2024-09-30 | $1,545 |
| 2024-06-30 | $1,492 |
| 2024-03-31 | $1,574 |
| 2023-12-31 | $1,513 |
| 2023-09-30 | $1,545 |
| 2023-06-30 | $1,378 |
| 2023-03-31 | $774 |
| 2022-12-31 | $742 |
| 2022-09-30 | $727 |
| 2022-06-30 | $724 |
| 2022-03-31 | $716 |
| 2021-12-31 | $672 |
| 2021-09-30 | $652 |
| 2021-06-30 | $666 |
| 2021-03-31 | $646 |
| 2020-12-31 | $631 |
| 2020-09-30 | $614 |
| 2020-06-30 | $600 |
| 2020-03-31 | $573 |
| 2019-12-31 | $587 |
| 2019-09-30 | $586 |
| 2019-06-30 | $601 |
| 2019-03-31 | $545 |
| 2018-12-31 | $514 |
| 2018-09-30 | $481 |
| 2018-06-30 | $452 |
| 2018-03-31 | $450 |
| 2017-12-31 | $451 |
| 2017-09-30 | $438 |
| 2017-06-30 | $444 |
| 2017-03-31 | $436 |
| 2016-12-31 | $428 |
| 2016-09-30 | $429 |
| 2016-06-30 | $409 |
| 2016-03-31 | $395 |
| 2015-12-31 | $390 |
| 2015-09-30 | $395 |
| 2015-06-30 | $399 |
| 2015-03-31 | $397 |
| 2014-12-31 | $389 |
| 2014-09-30 | $401 |
| 2014-06-30 | $397 |
| 2014-03-31 | $345 |
| 2013-12-31 | $339 |
| 2013-09-30 | $0 |
| 2013-06-30 | $0 |
| 2013-03-31 | $0 |
| 2012-12-31 | $317 |
| 2012-09-30 | $0 |
| 2012-06-30 | $0 |
| 2012-03-31 | $0 |
| 2011-12-31 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.924B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |